Blood Screening Market Is Projected To Witness Growth Based On Increasing Screening Of Donor & Continuous Technological Advancements By The Market Players Till 2024:Grand View Research,inc.
The global blood
screening market is
expected to reach a value of USD 3.9 billion by 2024, based on a new report by
Grand View Research, Inc. The growth of the market is attributed to the
increasing screening of donor and continuous technological advancements by the
market players. Demand for blood screening tests are increasing continuously
due to increasing donation, rising awareness about transfusion-transmitted
diseases, and technological developments in the industry.
Thorough screening is necessary
for all donated blood to ensure that recipients receive the safest products. As
of 2015, such testing consists of screening for red cell antibodies, and the
infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus
(WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T.
pallidum (syphilis). Result of all these assays must be negative for
blood donation.
Technological developments in the
market increase the sensitivity and efficiency of the tests. For instance, in
2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc.
and Grifols to screen donated blood. Furthermore, the U.S. FDA approved
next-generation sequencing (NGS) technology in 2013. The technology is cheaper
and faster than previous DNA analysis methods.
U.S. blood screening market by product, 2013 - 2024 (USD
Million)
Browse full research report on Blood
Screening Market
Further key findings from the report suggest:
- Nucleic acid
amplification test or nucleic acid test (NAT) is expected to be the
fastest growing segment during the forecast period. It comprises
transcription mediated amplification (TMA) tests and polymerase chain
reaction. Increasing demand of NAT over ELISA test due to high sensitivity
and specificity for viral nucleic acid is contributing to the fastest
growth during the forecast period.
- In 2015,
reagent dominated the product segment. Introduction of new assays for the
detection of various diseases is expected to enable the segment to gain
the maximum share of market in the coming years. For instance, in January
2015 the FDA approved Roche’s blood screening assay COBAS TaqScreen MPX
Test for the detection and identification of HCV, HIV, and HBV.
- In 2015,
regionally North America dominated with a revenue share of more than 40%.
Government initiatives, presence of major players, and more patient
affordability are the major factors that contributed toward its dominance.
- In August
2016, the FDA recommended the testing of all the donated blood in the U.S.
and its territories for Zika virus in order to prevent transmission of
this virus through the blood supply.
- Asia Pacific
is expected to be the fastest growing region due to increasing investment
of industry players, government initiatives, and rising awareness about
transmission of diseases during its transfusion.
- The Red Cross
in Japan entered into a contract with Grifols for nucleic acid testing
(NAT) for a blood donation camp in Japan in 2014. This agreement is
anticipated to propel the NAT market during the forecast period. However,
low donation as compared to requirement and high cost of kits and
instruments are likely to restrain the growth in low-income countries
during the forecast period.
For more information: http://www.grandviewresearch.com
Comments
Post a Comment